CatalentNYSE: CTLT

Catalent's stock is experiencing uncertainty because many pharmaceutical companies are worried about possible reduced competition after the acquisition, particularly in the production of weight-loss medications.

CTLT has announced that it has reached an agreement to sell its facility in Somerset, which focuses on the development and manufacturing of oral solid medications, to Ardena.

Catalent announced on Monday that it will sell its facility in Somerset, New Jersey, which focuses on oral drug development and small-scale manufacturing, to the private contract drug manufacturer Ardena.

On October 14, 2024, in Ghent, Belgium, Ardena, a pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in several countries, announced that it has finalized an agreement to purchase Catalent's advanced facility in Somerset, New Jersey. This acquisition will greatly improve Ardena's ability to manufacture oral drug products on a smaller scale during the later stages of development. It aligns with Ardena's goal to become a top global CDMO that provides comprehensive solutions throughout the pharmaceutical development process.

U.S. Senator Elizabeth Warren has urged antitrust regulators to carefully examine a $16.5 billion agreement where Novo Nordisk's main shareholder plans to buy contract drug maker Catalent. She believes this deal could provide the pharmaceutical company an unfair edge in the market for weight loss and obesity medications.

Catalent (CTLT) has received a Zacks Rank #1 (Strong Buy) upgrade, indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price in the short term.

On Friday, Catalent announced that it could not submit its annual report to regulators on schedule because it needs more time to finish "certain processes."

CTLT's strong results in different areas contributed to a positive performance in the fourth quarter, which caused share prices to rise in after-hours trading.

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.